Skip to Content

Valtropin

Active Substance: somatropin
Common Name: somatropin
ATC Code: H01AC01
Marketing Authorisation Holder: BioPartners GmbH
Active Substance: somatropin
Status: Withdrawn
Authorisation Date: 2006-04-24
Therapeutic Area: Dwarfism, Pituitary Turner Syndrome
Pharmacotherapeutic Group: Pituitary and hypothalamic hormones and analogues

Therapeutic Indication

Paediatric poulation

  • Long-term treatment of children (2 to 11 years old) and adolescents (12 to 18 years old) with growth failure due to an inadequate secretion of normal endogenous growth hormone.
  • Treatment of short stature in children with Turner syndrome, confirmed by chromosome analysis.
  • Treatment of growth retardation in pre-pubertal children with chronic renal insufficiency.

Adult patients

  • Replacement therapy in adults with pronounced growth hormone deficiency of either childhood- or adult-onset aetiology.

Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated growth hormone deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like growth factor-1 (IGF-1) concentrations (< 2 standard deviation score (SDS)), who may be considered for one test. The cut-off point of the dynamic test should be strict.

The marketing authorisation for Valtropin has been withdrawn at the request of the marketing-authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide